| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | CD158 antigen-like family member A, KIR2DL1, Killer cell immunoglobulin-like receptor 2DL1, Natural killer-associated transcript 1, NKAT-1, MHC class I NK cell receptor, CD158A, p58 natural killer cell receptor clones CL-42/47.11, CD158a, p58.1 MHC class-I-specific NK receptor, NKAT1, p58 NK receptor CL-42/47.11, p58 NK receptor CL-43, NKAT-6, NKAT6, MHC class I NK cell receptor, CD158 antigen-like family member B1, CD158b1, p58 natural killer cell receptor clone CL-43, Natural killer-associated transcript 6, CD158B1, KIR2DL2, Killer cell immunoglobulin-like receptor 2DL2, P58 natural killer cell receptor clones CL-39/CL-17, CD158i, MHC class I NK cell receptor, CD158I, p58 NK receptor CL-39/CL-17, NKAT8, KKA3, NKAT-8, CD158 antigen-like family member I, Killer cell immunoglobulin-like receptor 2DS4, Natural killer-associated transcript 8, KIR2DS4 |
| Clonality | |
| Concentration | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target |
Overview
Anti-Human CD158a/b1/b2/h/j Antibody (SAA0063) targets CD158a (p58 natural killer cell receptor clones CL-42/47.11). Frequently used across FCM workflows, depending on experimental design and sample type. This antibody is suited for workflows commonly used in Immunology & Inflammation research.
Also known as: p58 natural killer cell receptor clones CL-42/47.11, P58 natural killer cell receptor clones CL-39/CL-17, p58 natural killer cell receptor clone CL-43, Killer cell immunoglobulin-like receptor 2DL1, Killer cell immunoglobulin-like receptor 2DL2, Killer cell immunoglobulin-like receptor 2DS4, p58.1 MHC class-I-specific NK receptor, MHC class I NK cell receptor, CD158 antigen-like family member B1, CD158 antigen-like family member A.
Target biology
CD158a (p58 natural killer cell receptor clones CL-42/47.11) encodes a receptor or receptor subunit involved in sensing extracellular or cell-surface cues and relaying signals to intracellular pathways. Receptor availability at the cell surface and activation state can vary with differentiation and stimulation conditions. Common alternative names and symbols used in the literature include: P58 natural killer cell receptor clones CL-39/CL-17, p58 natural killer cell receptor clone CL-43, Killer cell immunoglobulin-like receptor 2DL1, Killer cell immunoglobulin-like receptor 2DL2, Killer cell immunoglobulin-like receptor 2DS4, p58.1 MHC class-I-specific NK receptor, MHC class I NK cell receptor, CD158 antigen-like family member B1, CD158 antigen-like family member A, CD158 antigen-like family member I. Based on the annotated name/class, the target is most often associated with plasma membrane and/or intracellular membranes localization, though this can vary by model system.
How this antibody helps
As a monoclonal reagent, this antibody is designed for clone-to-clone consistency and epitope-focused recognition. For best performance, interpret signal in the context of appropriate biological controls and orthogonal readouts when available.
Recommended experimental notes
- Titrate the antibody to optimize signal-to-noise for your specific sample type and detection system.
- Use appropriate positive and negative controls (e.g., target-high vs target-low samples, KO/KD where available).
For research use only. Not for diagnostic procedures.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.